Cue Biopharma (CUE) EPS (Basic) (2017 - 2025)

Cue Biopharma (CUE) posted EPS (Basic) of $0.62 for Q4 2025, up 125.54% sequentially from -$2.43 in Q3 2025, and up 112.7% YoY from $0.29 in Q4 2024.

Cue Biopharma (CUE) EPS (Basic) (2017 - 2025) Analysis & Trends

Cue Biopharma has reported EPS (Basic) for 9 years, with the latest figure at $0.62 in Q4 2025.

Quarterly EPS (Basic) rose 112.7% year-over-year to $0.62 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.71 (up 58.74% YoY) and the FY2025 annual result came in at -$8.88, up 55.81% from the prior year.
EPS (Basic) rose to $0.62 in Q4 2025 per CUE's latest filing, from -$2.43 in the prior quarter.
Over five years, EPS (Basic) peaked at $0.62 in Q4 2025 and troughed at -$18.56 in Q1 2021.
A 5-year average of -$8.77 and a median of -$9.18 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) plunged 67.69% in 2022, then surged 112.7% in 2025.
Over 5 years, EPS (Basic) stood at -$7.57 in 2021, then sank by 67.69% to -$12.69 in 2022, then surged by 31.99% to -$8.63 in 2023, then jumped by 43.32% to -$4.89 in 2024, then surged by 112.7% to $0.62 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered $0.62, -$2.43, and -$4.58 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	12.62
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	7.59
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	1.23
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	-0.72
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	0.18
10	Cue Biopharma	150.85 Mn	133.43 Mn	-	-13.81

Download Data